Medicare Advantage 2026 Spotlight: A First Look at Plan Premiums and Benefits
This brief provides an overview of premiums and benefits in Medicare Advantage plans that are available for 2026 and key trends over time.
Search
-
-
KFF Follow-Up Survey of Marketplace Enrollees: Following End of Enhanced Credits, Half of Marketplace Enrollees Now Say Costs Are a Lot Higher, Most Expect to Cut Back on Basic Household Expenses to Afford Coverage
News ReleaseFollowing the expiration of the enhanced premium tax credits for people with Affordable Care Act (ACA) Marketplace plans, a new KFF follow-up survey of the same Marketplace enrollees KFF surveyed in 2025 finds half (51%) of returning enrollees say their health care costs are “a lot higher” this year compared to last year, including four in ten who specifically say their premiums are “a lot higher.”
-
Claims Denials and Appeals in ACA Marketplace Plans in 2024
Issue BriefThis brief analyzes federal transparency data published by CMS on claims denials and appeals for Marketplace plan offered on HealthCare.gov in 2024, and finds insurers denied 19% of in-network claims. Consumers rarely appeal denied claims.
-
Why is There So Much Attention on Obesity Drugs?
Quick TakeHigh U.S. prices and demand for Ozempic and Wegovy have implications for insurance premiums, public program costs, and affordability.
-
Marketplace Insurers are Proposing a 7% Average Premium Hike for 2025 and Pointing to Rising Hospital Prices and GLP-1 Drugs as Key Drivers of Costs
News ReleaseACA Marketplace insurers are proposing a median premium increase of 7% for 2025, similar to the 6% premium increase filed for 2024, according to a new KFF analysis of the preliminary rate filings. Insurers’ proposed rate changes – most of which fall between 2% and 10% – may change during the review process.
-
Millions of People with Medicare Will Benefit from the New Out-of-Pocket Drug Spending Cap Over Time
Issue BriefIn 2025, Medicare beneficiaries will pay no more than $2,000 out of pocket for prescription drugs covered under Part D, Medicare’s outpatient drug benefit, due to a provision in the Inflation Reduction Act of 2022. This analysis examines how many Medicare Part D enrollees spent $2,000 or more out of pocket in 2021 and over multiple years, both nationally and at the state level, to show how many people over time could benefit from the new Part D spending cap.
-
3 Charts: Medicare Drug Price Negotiations
News ReleaseUnder the Inflation Reduction Act, the federal government for the first time will negotiate directly with drug companies to determine the prices that Medicare will pay for certain high expenditure drugs covered under Medicare Part D (starting in 2026) and Part B (starting in 2028).
-
KFF Health Tracking Poll May 2024: The Public’s Use and Views of GLP-1 Drugs
FeatureKFF’s latest Health Tracking Poll examines the public’s views and use of an an increasingly popular class of prescription drugs used for weight loss and to treat diabetes or prevent heart attacks or strokes. The poll finds 12% of adults report having taken one of these GLP-1 drugs, which include Ozempic, Webovy and Mounjaro. This includes 6% who say they are currently taking one of the drugs.
-
KFF Tracking Poll on Health Information and Trust: Vaccine Safety and Trust
Poll FindingAs the Trump administration overhauls government health agencies, partisan trust in these agencies on vaccines has shifted and few express confidence in their ability to carry out key tasks. Most adults are confident in the safety of routine vaccines, but the COVID-19 vaccines remain polarizing with many uncertain about false claims regarding mRNA technology.
-
2025 California Health Benefits Survey
ReportThe survey provides an in-depth look at trends in employer-sponsored coverage in California, including premiums, cost sharing, offer rates, and employer strategies to manage costs and access to care, including comparisons to the nation overall.